Analytical Data
-
Gene name
MTMR7
- Application
-
Alternative Names
MTMR7; Myotubularin-related protein 7; Inositol 1,3-bisphosphate phosphatase; EC 3.1.3.-; Phosphatidylinositol-3-phosphate phosphatase; EC 3.1.3.64
-
Species
Human
-
Source
E. coli
-
Tag
N- His-SUMO
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9Y216
-
Expression Region
1-660aa
-
Molecular Weight
91.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MTMR7 (Myotubularin-related protein 7) is a member of the myotubularin family, which is characterized by its lipid phosphatase activity involved in the regulation of phosphoinositides, critical for various cellular processes, including membrane trafficking and cytoskeletal dynamics. Mutations in the MTMR7 gene are associated with human disorders, particularly Charcot-Marie-Tooth disease type 4B (CMT4B), a hereditary neuropathy that leads to progressive muscle weakness and atrophy. The study of MTMR7 recombinant protein has gained significant interest as understanding its enzymatic properties and interactions can provide insights into the pathogenesis of CMT4B and other related conditions. Research has focused on characterizing the protein's structure, function, and the impact of specific mutations on its activity, which are crucial for developing therapeutic interventions. Moreover, examining MTMR7's role in phosphoinositide metabolism can illuminate its broader involvement in cellular signaling pathways and its potential implications in neurodegenerative diseases. By producing recombinant MTMR7, scientists aim to facilitate structure-function studies and high-throughput screening for small molecules that could modulate its activity, ultimately leading to novel therapeutic strategies for patients affected by MTMR7-related disorders. As our understanding of MTMR7 evolves, it poses significant potential for advancing treatments for inherited neuropathies and enhancing our knowledge of cellular mechanisms underlying these complex diseases.
